Bispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...

Viruses like the one that causes COVID-19 constantly mutate, rendering many antibody treatments ineffective. A Stanford-led ...

A Stanford-led team has found two antibodies that can work together to neutralize the virus that causes COVID-19 in all its ...

ImmunoPrecise Antibodies has secured a collaboration with an undisclosed “leading biotech” to discover new antibody-drug ...

Panelists discuss how recent FDA approvals for bispecific antibodies in oncology, particularly for hematologic malignancies ...

The virus that causes COVID-19 has been very good at mutating to keep infecting people—so good that most antibody treatments developed during the pandemic are no longer effective. Now a team led by ...

US-based startup Bambusa Therapeutics has secured $90m in Series A financing to advance its pipeline of bispecific antibodies for immunological and inflammatory disorders into the clinic.

SHANGHAI, March 5, 2025 /PRNewswire/ -- SanyouBio announced today the official launch of 73 whole-series bispecific antibody reference products, covering globally approved and representative ...

The syndrome can be difficult to distinguish from sepsis. Its incidence varies by bispecific antibodies and disease subtype; most cases of CRS are low grade (1 and 2), occurring in as many as 50% of ...

TOPLINE: Bispecific antibodies (BsAbs) demonstrated a manageable safety profile in patients with non-Hodgkin lymphoma (NHL), with 48% prevalence of all-grade cytokine release synd ...

Geoffrey Shouse, DO, PhD, discusses the growing interest in bispecific antibodies within the field of oncology.

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting immunological and inflammatory (I&I) conditions. New investor RA Capital ...